Background
Systemic lupus erythematosus (SLE) is a disease with heterogeneous involvement and mostly affects female subjects (1) . Around 23% to 60% of SLE patients presented with renal involvement caused by inflammation which consequently leads to deposition of the glomerular immune complex. The clinical manifestations of renal disease occur in around half of the SLE patients. The www.nephropathol.com
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M694V mutation in SLE 375 most evidences for renal involvement appear within the first 6 to 36 months of diagnosis (2, 3) . Positive antinuclear antibodies (ANAs), elevated anti-DNA, low complement levels and renal manifestations often indicate active lupus, particularly lupus nephritis. Nephritis relapse is a strong predictor of progression to end-stage renal disease (ESRD) (4) . SLE patients have disruptions in their innate immunity that could play a critical role in initiation and prolongation of the disease (5) . In course of infections, neutrophils release neutrophil extracellular traps (NETs) which this process is known as NETosis and results in cell death. In SLE, NETosis occurs after neutrophil priming and activation respectively by type I interferon and cytokines (IL-1β, IL-8, IL-17 and TNF) and autoantibodies (6, 7) . Enhanced NET formation and impaired clearance may lead to immunogenicity in SLE by induction of the modified autoantigens externalization, such as synthesis of type I interferon, stimulation of the inflammasome, and activation of the complement system pathways (8) . This can result to the release of more cytokines which further stimulate NETosis. Excess NETosis can potentially cause organ damage (9) .
Mediterranean fever gene (MEFV) mutations develop the familial Mediterranean fever (FMF), an autosomal recessive disease. MEFV gene consists of 10 exons and is located on chromosome 16p13.3 (10) . This gene encodes marenostrin/pyrin protein and has a vital role in the inflammatory responses (11) . From MEFV gene mutations, the M694V mutation (c.2080A>G) in exon10 is the most common and disease-causing variation that has been presented in all studied groups (12, 13) . M694V mutation leads to the loss of inhibitory effects of the C-terminal B30.2 domain of pyrin protein on caspase-1 and other components of the inflammasome (14).
The most serious problem of FMF is the development of kidney amyloidosis that is highly associated with the M694V substitution (15) and results in renal insufficiency leading to ESRD (16) .
The possible relation between FMF and SLE has been reported previously. In spite of the differences, numerous same pathogenic mechanisms are shared between these two disorders. Additionally, they have the same clinical conditions, like renal involvement (17, 18) .
Releasing of the NETs along with IL-1β was observed in the course of disease attacks in both of diseases (19) .
Additionally, some cases of SLE with AA amyloidosis have been reported previously. In SLE cases, deposition of amyloid fibrils has been observed in some organs including gastrointestinal tract, heart, skin, and mostly in kidney which causes insufficiency of renal function (20, 21) .
Further scientific information on the role of innate immunity in SLE pathogenesis including the role of the pyrin domain on the inflammasomes activation makes the possible effect of MEFV mutation on SLE manifestations (22) .
Objectives
The idea of the current study came up with the aim of discovering the clinical significance of the M694V gene mutation in SLE patients. MEFV mutations have been studied before in a variety of auto-inflammatory and autoimmune diseases in Iranian patients. However, the role of these mutations in the susceptibility of SLE in Iranian population is not clear. This study was aimed to evaluate the potential influences of M694V gene mutation in SLE disease, particularly in development of renal involvement in Iranian SLE patients.
Patients and Methods

Study population
The present study included 130 SLE cases and 116 healthy controls. Of 130 SLE patients, 113 patients were female and 17 were male (female to male ratio of 7.53:1), thus, the majority of SLE patients were female.
The mean age of patients was 22.31 ± 8.351 years and the mean duration of SLE was 4.85 ± 2.901 years. The patients met at least four criteria of American College of Rheumatology (ACR) for SLE disease (17) . The study was established by the local ethics committee. All of the individuals joined in this study voluntarily and after clarification of the aim of the study informed consents were attained from all cases. The laboratory and clinical features of the patients were recorded using a standard form.
DNA extraction and mutation analysis
For each patient, DNA extraction was done from whole blood. Each DNA sample was genotyped for M694V www.nephropathol.com 376
Ethical issues
1) The research followed the tenets of the Declaration of Helsinki and its later amendments; 2) informed consent was obtained; and 3) This study was allowed by the Ethics Committee of Shahid Beheshti University, Tehran, Iran (#D-200-2782).
Statistical analysis
Statistical analysis was carried out using SPSS version 22. Differences between the groups in separate variables were compared using a chi-square test (Pearson or Fisher's exact test was applied whenever needs), and odds ratios (OR) were given with 95% CIs. Results were given as a mean ± standard deviation (SD). Statistical significance was defined as P < 0.05.
Results
One hundred thirteen (86.9 %) of patients (n = 130) were female. The mean age of total patients was 22.31 ± 8.351 years and the mean age of SLE onset was 17.14 ± 7.332 years. The mean age of lupus nephritis patients with positive ANA, elevated anti-DNA, low complements (C3 and C4) levels and renal manifestations was 21.35 ± 7.656. Their mean age of lupus nephritis onset was 15.88 ± 5.666 and the mean duration of their lupus nephritis was 5.47 ± 2.501. Patients in the SLE nephritis group were younger. The disease onset was around one year earlier and disease duration was a little higher compared to non-nephritis lupus patients. All subjects were genotyped for M694V gene variation. A significant association for allelic and genotypic frequency of the M694V mutation between SLE patients and controls was observed (9.9% vs. 2.4%, P = 0.000, OR = 4.277, CI = 2.213-8.265).
No mutations were identified in 91 of patients (70%), although we cannot ignore the probability that some of the patients had other mutations. The M694V mutation carriage rate in our SLE patients was 18.8%. Renal involvements were more significant in M694V carriers than those in non-carriers (8.5% versus 10.4%, P=0.017, OR= 2.149, CI= 1.135-4.072) ( Table 1 ).
There were no significant differences in other clinical manifestations and laboratory abnormalities between SLE patients and M694V mutation occurrence.
Additionally, no significant difference of SLE onset in patients with M694V mutation (15.76 ± 7.60 versus 18.53 ± 7.15 years, carriers versus non-carriers, P= 0.084) was observed.
Discussion
In this study, the frequency of the M694V gene variation in SLE patients was investigated. This mutation is the most important variation that has been reported previously in FMF patients. Therefore, further studies in other diseases helps to accurately explain the nature of the inflammatory state in M694V mutation carriers.
Moreover, how it can influences SLE pathogenesis, along with other autoimmune disorders is remarkable. The M694V mutation carriage rate in our SLE patients was 18.8%. We found a statistically significant difference between SLE patients and matched healthy controls for allelic and genotypic frequencies (P = 0.001). (26) . Increased NET release, NETosis, and impaired NET clearance were detected in SLE patients (27) . Furthermore, we studied the effect of M694V occurrence on the lupus phenotype such as renal involvement. To the best of our knowledge, the relation of the M694V mutation and SLE phenotype has not been previously reported in Iranian population.
Renal involvement developed in 30% of our patients that is in accordance with previous studies (3). 
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We observed a statistically significant difference between M694V carriers and non-carriers in our SLE patients with renal involvement. Therefore, the M694V mutation is likely to be an important factor in developing renal involvement in SLE patients especially in lupus nephritis. (28) . However, the modifying role of M694V mutation on the clinical manifestation of SLE is not supported by our results. This finding is in contrast to the study by Shinar et al (29) . It may be explained by different frequency of alleles and genotypes and different penetration between populations. According to our observation, it could manifest itself in both homozygote and heterozygous states in patients with renal involvement. Our results are in agreement with the study of Deniz et al (30) . They reported an association between exon 10 mutations of MEFV gene including M694V variation with lupus nephritis. Our findings may be partially explained by the excessive IL-1β production along with neutrophil activation which results to more profound inflammatory state associated with M694V. This condition may lead to overreaction to infections or to any other stimulus. This causes overwhelming of NET formation and release (31) . NETs contain autoantibodies and C1q, which prevents DNase-I access to NETs and also degradation of chromatin (27) .
Impairment of DNase I function leads to failure of dismantling NETs and cause to more IL-1β production (31, 32) . On the other hand, the inhibitory effect of DNase I on IL-1β production was altered through its inhibition (19) . All of these consequences correlated with kidney involvement. The immune complexes may get deposited in the kidneys, leading to lupus nephritis. Moreover, NETs stimulate interferon-α release, which can directly damage tissues. It is also demonstrated to be associated with lupus nephritis (9, 31) . Finally, the uncontrolled inflammatory response leads to autoimmune-mediated renal involvement, which is due to M694V mutation in pyrin protein.
Furthermore, M694V is associated with amyloidosis or amyloid production in familial Mediterranean fever (33) .
The defective pyrin protein loses its direct or indirect anti-amyloid effect, leading to a deposition of amyloid fibrils (15) . Moreover, mutations that cause an alteration in native peptides or inflammatory processes leads to abnormal protein folding that may develop amyloid fibril deposition (34) .
Secondary amyloidosis (AA amyloidosis) was reported in certain autoimmune diseases, such as rheumatoid arthritis and dermatomyositis. Therefore, it would not be unexpected to occur in SLE (35) . AA amyloidosis associated with SLE may affect several organ and tissues such as the kidney, gastrointestinal tract, liver, spleen, heart, lung, and bone marrow (36, 37) . AA amyloidosis may be associated with long-standing SLE (36) . The development of renal involvement is a potentially lethal complication of SLE. Despite all of the challenges, advances in understanding the biological basis of SLE can suggest more effective approaches to patient care.
Early diagnosis and prompt treatment decrease morbidity and mortality of the disease.
Conclusions
In conclusion, we found the M694V mutation could be an additional genetic susceptibility cause of SLE disease and development of renal involvement. Future studies focusing on the presence of the M694V mutation in SLE patients are required to provide more reliable and conclusive results.
Limitations of the study
This study should be considered as an initial finding.
Therefore, larger proportion of patients in independent studies with a wider spectrum of MEFV variations is needed to define its exact role in this disease. Additionally, the frequency of alleles and genotypes may be different between populations. Hence, the association studies of MEFV gene with SLE disease in various populations can lead to more accurate understanding about the impact of this mutation on SLE susceptibility and help to develop new treatments.
